CHAPTER 3 56 Table 1. Baseline characteristics of the included study cohort according to the four molecular subgroups Total N=393 POLE-mutant N=33 (8.4%) MSI N=78 (19.8%) TP53-mutant N=72 (18.3%) NSMP N=210 (53.4%) P Patient characteristic Age (years) 64.0 (31.0-86.0) 58.0 (31.0-78.0) 65.0 (43.0-83.0) 64.5 (35.0-82.0) 63.5 (37.0-86.0) .001 BMI kg/m2 29.1 (18.0-58.3) 31.3 (18.4-58.3) 29.5 (21.90-46.9) 31.2 (21.2-41.1) 27.0 (18.0-38.9) .004 Primary treatment Lymph node dissection No 12 (3.1) 0 (0.0) 3 (3.8) 2 (2.8) 7 (3.3) .26 Yes 376 (95.7) 33 (100.0) 75 (96.2) 67 (93.1) 201 (95.7) Pelvic 214 (56.9) 21 (63.6) 47 (62.7) 25 (37.3) 121 (60.2) Para-aortic 13 (3.4) 0 (0.0) 1 (1.3) 4 (6.0) 8 (4.0) Pelvic and para-aortic 54 (14.4) 4 (12.1) 8 (10.7) 12 (17.9) 30 (14.9) Unknown which nodes 95 (25.3) 8 (24.2) 19 (25.3) 26 (38.8) 42 (20.9) Unknown 5 (1.3) 0 (0.0) 0 (0.0) 3 (4.2) 2 (1.0) Final pathologic characteristics Histology EEC 318 (80.9) 28 (84.8) 69 (88.5) 41 (56.9) 180 (85.7) <.001 NEEC 75 (19.1) 5 (15.2) 9 (11.5) 31 (43.1) 30 (14.3) Grade 1-2 209 (53.2) 17 (51.5) 41 (52.6) 13 (18.1) 138 (65.7) <.001 3 184 (46.8) 16 (48.5) 37 (47.4) 59 (81.9) 72 (34.3) MI <50% 197 (50.1) 13 (39.4) 42 (53.8) 32 (44.4) 110 (52.4) .14 >50% 194 (49.4) 19 (57.6) 35 (44.9) 40 (55.6) 100 (47.6) Unknown 2 (0.5) 1 (3.0) 1 (1.3) 0 (0.0) 0 (0.0) LVSI No 304 (77.4) 27 (81.8) 64 (82.1) 41 (56.9) 172 (81.9) <.001 Yes 89 (22.6) 6 (18.2) 14 (17.9) 31 (43.1) 38 (18.1) Lymph nodes N0 305 (77.6) 29 (87.9) 68 (87.2) 46 (63.9) 162 (77.1) .02 N1 43 (10.9) 1 (3.0) 5 (6.4) 13 (18.1) 24 (11.4)
RkJQdWJsaXNoZXIy MTk4NDMw